King Pharmaceuticals Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Bristol TN United States (1994)
Status: Acquired by Pfizer (2010)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1994
procaine benzylpenicillin (novocaine)
First NDA Approval
1999
quinupristin
Last Known Activity
2002

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

KING PHARMS | KING PHARMS LLC

Active Ingredients

Marketed Drugs (27)

Key: King Pharmaceuticals (25) Acquired (2)

aminophylline (aminophyllin)

bendroflumethiazide (naturetin) (1983)

chloramphenicol (chloromycetin) (1951 NDA)

chlorthalidone (Hygroton) (2005)

cromoglicic acid (Intal) (1982)

dalfopristin (Synercid) (1999)

gentamicin (garamycin)

homatropine (1985)

hydrocodone (hycodan) (1985)

kanamycin (Kantrex)

levothyroxine (Synthroid) (2001)

liothyronine (cytomel) (1956 NDA)

loracarbef (lorabid) (1991)

metaxalone (skelaxin) (1962 NDA)

methimazole (tapazole) (1950 NDA)

metoclopramide (reglan)

morphine (2002)

nadolol (corgard) (1983)

naltrexone (revia) (2009)

nedocromil (tilade) (1992)

procainamide (pronestyl) (1996)

procaine benzylpenicillin (novocaine) (1948)

quinidine

quinupristin (1999 NDA)

ramipril (altace) (1991)

silver sulfadiazine (silvadene) (1973 NDA)

trimethobenzamide (tigan) (1974)

Drugs in Phase 4 Trials (1)

Key: King Pharmaceuticals (0) Acquired (1)

morphine (3 trials)

Drugs in Phase 3 Trials (2)

Key: King Pharmaceuticals (0) Acquired (2)

naltrexone (revia) (2 trials)

simvastatin (zocor) (1 trial)

Overview

  • Highest Phase: None
  • # of Trials: 4
  • # of Trial APIs: 3